Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
Open Access
- 1 January 2019
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 10, 1-13
Abstract
The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors commonly used to treat immune thrombocytopenia (ITP). There are three agents that have been investigated for the treatment of chronic ITP: the peptide agent romiplostim and the small molecule agents eltrombopag and avatrombopag. These agents offer a higher clinical response rate than most other ITP therapies but may require indefinite use. This review is a critical appraisal of the TPO-RAs in adult ITP, defining the optimal patient groups to receive these agents and assisting the hematologist with agent choice, goals of treatment, dosing strategies, and toxicity management. Use of endogenous thrombopoietin levels to predict response to eltrombopag and romiplostim treatment is discussed and alternative dosing protocols suited for certain patient subgroups are described. Finally, indications for discontinuation and combination therapy with other agents are considered.Keywords
This publication has 71 references indexed in Scilit:
- Platelet aggregation response in immune thrombocytopenia patients treated with romiplostimAnnals of Hematology, 2018
- Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopeniaAmerican Journal of Hematology, 2018
- A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablationJournal of Gastroenterology, 2018
- Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 InhibitorsThe Journal of Clinical Pharmacology, 2018
- Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White SubjectsClinical Pharmacology in Drug Development, 2017
- Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopeniaAnnals of Hematology, 2016
- Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopeniaAmerican Journal of Hematology, 2014
- TPO concentrations and response to romiplostimAmerican Journal of Hematology, 2014
- Thrombopoietin levels in patients with disorders of platelet production: Diagnostic potential and utility in predicting response to TPO Receptor agonistsAmerican Journal of Hematology, 2013
- Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopeniaQuality of Life Research, 2011